Laekna and Eli Lilly & Co. Enter Clinical Cooperation to Advance Obesity Treatment LAE102
Sino-US biotech company Laekna, Inc. (HKG: 2105) has announced a significant clinical cooperation agreement with...
Obesity
Novo Nordisk Launches Semaglutide for Weight Management in China
Denmark-based healthcare giant Novo Nordisk A/S (NYSE: NVO) has announced the official market launch of...
Eli Lilly’s Tirzepatide Shows Sustained Weight Loss in 176-Week Study
US pharmaceutical giant Eli Lilly and Company (NYSE: LLY) has released 176-week follow-up data from...
Sunshine Lake Pharma Inks Licensing Deal with Apollo Therapeutics for APL-18881
China-based Sunshine Lake Pharma Co., Ltd., (HKG: 1558) a member of the HEC Group, has...
Gan & Lee’s GZR18 Shows Significant Weight Loss in Phase IIb Study at ObesityWeek 2024
Gan & Lee Pharmaceuticals (SHA: 603087), a China-based pharmaceutical company, has announced the oral presentation...
Ascletis Pharma’s ASC47 Showcases Promising Weight Loss Results in Phase I Clinical Trial
Ascletis Pharma Inc. (HKG: 1672), a China-based pharmaceutical company, has announced positive results from a...
Novo Nordisk Secures Global Licensing Agreement with Ascendis Pharma for TransCon Technology
Denmark-based healthcare giant Novo Nordisk (NYSE: NVO; CPH: NOVO-B) has entered into a licensing agreement...
Eli Lilly’s Mounjaro Approved in Hong Kong for Obesity and Type 2 Diabetes Treatment
Eli Lilly & Co. (NYSE: LLY) has received market approval from Hong Kong’s Department of...
Humanwell Healthcare Receives NMPA Approval for Chemically Synthesized Semaglutide Clinical Trial
Humanwell Healthcare (Group) Co., Ltd (SHA: 600079), a leading healthcare company based in China, has...
Eccogene Inc. Secures $60 Million Milestone Payment from AstraZeneca for ECC5004/AZD5004
Sino-US firm Eccogene Inc. announced on October 23rd that it is set to receive a...
Novo Nordisk’s Semaglutide Shows 14% Reduction in Cardiovascular Events in Landmark SOUL Trial
Copenhagen-based healthcare giant Novo Nordisk (NYSE: NVO) has declared the primary outcomes of the SOUL...
Novo Nordisk Expands Legal Campaign to 50 Cases Against Semaglutide Compounders
Novo Nordisk (NYSE: NVO) has escalated its legal battles in the healthcare sector by filing...
BrightGene’s BGM0504 Shows Promise in Phase II Obesity Study Without Diabetes
BrightGene Bio-Medical Technology Co., Ltd (SHA: 688166), a Chinese biopharmaceutical company, has announced positive results...
Huadong Medicine Secures NMPA Approval for Semaglutide Biosimilar, Aims to Capture Weight Loss Market
Nanjing-based Huadong Medicine Co., Ltd (SHE: 000963) has received clinical trial approval from China’s National...
Eli Lilly Expands Collaboration with KeyBioscience to Develop Obesity Treatments Using DACRA Platform
Eli Lilly and Company (NYSE: LLY) has announced an extension of its collaboration with KeyBioscience...
Eli Lilly & Co. Boosts Suzhou Plant with $211M to Meet Diabetes and Obesity Drug Demand
Eli Lilly & Co.(NYSE: LLY)’s China subsidiary is poised to invest a substantial RMB 1.5...
Kailera Therapeutics Emerges with USD 400 Million in Series A Funding for Anti-Obesity Pipeline
Kailera Therapeutics, a newly launched US-based biotechnology company, secured USD 400 million in Series A...
Ascletis Pharma Initiates Phase I Trials for Monthly Subcutaneous and Daily Oral Obesity Treatment ASC30 in the US
Ascletis Pharma Inc. (HKG: 1672), a biopharmaceutical company based in China, has announced the dosing...
Innovent Biologics’ Mazdutide Outperforms Dulaglutide in Phase III T2D Study at EASD Meeting
Innovent Biologics, Inc. (HKG: 1801), a biopharmaceutical company based in China, has presented significant findings...
Eli Lilly Partners with Haya Therapeutics to Tap the Dark Genome for Obesity Treatments
Eli Lilly & Co. (NYSE: LLY), a leading figure in the pharmaceutical industry, has embarked...